. 2020 Jun 30;5:108. doi: 10.1038/s41392-020-00216-5

Table 1.

Clinical trials and preclinical drugs targeting ferroptosis and lipid metabolism for antitumor treatment

Nos.	Drugs	Target	Clinical use/clinical trials	Refs.
1	Sorafenib	System $x_{c}^{-}$ inhibitor	Renal cell, thyroid, and hepatocellular carcinoma treatment	^135–137
2	Altretamine	GPX4 inhibitor	Ovarian cancer treatment	^139,140
3	Buthionine sulfoximine	γ-GCS inhibitor	Clinical trials for neuroblastoma treatment	^21,42,96
4	Statins	Block biosynthesis of CoQ10	Cholesterol reducing agents	⁸³
5	Sulfasalazine	System $x_{c}^{-}$ inhibitor	Rheumatoid arthritis and inflammatory bowel diseases treatment/clinical trials for glioma treatment	^135,138
6	Lapatinib and neratinib	Kinase inhibitor and alters iron transport system	Clinical trials for solid and metastatic breast cancer treatment	^141,142
7	BAY-87-2243	Mitochondrial complex I inhibitor/HIF-1 inhibitor	Phase I trial for treatment of advanced malignancies	¹⁴³
8	Salinomycin	Antioxidant properties inhibitor and alters iron transport system	Preclinical trials for breast cancer treatment	^144–146
9	MF-438	SCD1 inhibitor	Preclinical trials for melanoma, breast and lung cancer treatment	^41,148–150
10	CAY10566	SCD1 inhibitor	Preclinical trials for breast, prostate and liver cancer treatment	^41,151–153
11	Aminooxyacetic acid	Mitochondrial fatty-acid synthesis	Preclinical trials for colon cancer treatment	^4,155,156
12	Triacsin C	ACSL1,3,4 inhibitor	Preclinical trials for cancer treatment	^47,157
13	thiazolidinediones	ACSL4 inhibitor	Diabetes/clinical trials for cancer treatment	^10,157
14	Zileuton	5-LOX inhibitor	Clinical trials for lung, head and neck cancer and chronic myelogenous leukemia treatment	^158–161
15	Baicalein	12/15-LOX inhibitor	Clinical trials for acute lymphocytic leukemia treatment	^29,162